New antibody aims to dissolve lung clots with less bleeding risk
NCT ID NCT05408546
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a new drug called TS23, a monoclonal antibody designed to help break down blood clots in the lungs. It is for people with intermediate-risk pulmonary embolism, a serious condition where clots block blood flow. The trial compares different doses of TS23 against a placebo to see if it safely dissolves clots and improves heart function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TS23 (a monoclonal antibody that targets a protein involved in blood clot breakdown)
What this could lead to
If successful, TS23 could offer a new, safer way to dissolve dangerous blood clots in the lungs, potentially reducing complications and improving recovery.
What could go wrong
This is an early phase 2 trial with only 64 participants, so results may not apply to everyone. The main risk is bleeding, and the drug may not work better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner University Medical Center
Phoenix, Arizona, 85004, United States
-
Banner University Medical Center - Tucson
Tucson, Arizona, 85004, United States
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Cottage Hospital
Santa Barbara, California, 93105, United States
-
Fairview Hospital
Cleveland, Ohio, 44111, United States
-
Henry Ford Hospital
Detroit, Michigan, 48207, United States
-
Lifebridge Health
Baltimore, Maryland, 21215, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
Texas Tech University Health Sciences Center at El Paso
El Paso, Texas, 79430, United States
-
Tuft University Hospital
Boston, Massachusetts, 02116, United States
-
Wake Forest University/Atrium Health's Carolinas Medical Center
Winston-Salem, North Carolina, 27103, United States
-
Wellstar MCG Health Medical Center
Augusta, Georgia, 30912, United States